Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic ...
– Data from multiple ongoing trials evaluating Vir's two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals – – Preliminary data to-date show that 30.8% of participants …